

FEB 12 2008



HAMRE, SCHUMANN, MUELLER & LARSON, P.C.

AN INTERNATIONAL INTELLECTUAL PROPERTY LAW FIRM

FAX TRANSMISSION February 12, 2008

TO: Mail Stop: AMENDMENT
Examiner: Unknown
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

FROM: Douglas P. Mueller

OUR REF: 10873.1912USWO

TELEPHONE: (612) 455.3800

Total pages, including cover letter: 7


PTO FAX NUMBER: 571.273.8300

If all pages are NOT received, please call us at 612.455.3800 or fax us at 612.455.3801.

Title of Document: Supplemental Information Disclosure Statement (3 pgs)
Form 1449 (1 pg); Copy of Australian Office Action dated
December 19, 2007 (2 pgs)


Applicant: KAWARABATA et al.
Serial No.: 10/581,732
App. Filed: June 6, 2006
Group Art No.: 3761

Please charge any additional fees or credit overpayment to Deposit Account No. 50-3478. Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers, if appropriate.

By: 
Name: Douglas P. Mueller
Reg. No. 30,300

I hereby certify that this paper is being transmitted by facsimile to the U.S. Patent and Trademark Office on the date shown below.

Mele Cauffman


Signature

Feb 12 2008
Date

225 SOUTH SIXTH STREET • SUITE 2650 • MINNEAPOLIS • MN 55402
TEL 612.455.3800 • FAX 612.455.3801
WWW.HSML.COM • MAIL@HSML.COM

FEB 12 2008


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: KAWARABATA et al. Examiner: Unknown
Serial No.: 10/581,732 Group Art Unit: 3761
Filed: June 6, 2006 Docket: 10873.1912USWO
Title: EXTRACORPOREAL BLOOD CIRCULATING APPARATUS,
CLOSED-TYPE VENOUS RESERVOIR AND EXTRACORPOREAL
BLOOD CIRCULATING METHOD

CERTIFICATE UNDER 37 C.F.R. 1.6(d)

I hereby certify that this paper is being transmitted by facsimile to the United States Patent and Trademark Office on February 12, 2008.

By:



Name: Mele Cauffman

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner. Please note the references cited on Form 1449 were cited in the Australian Office Action dated December 19, 2007. Copies of any foreign patent documents or "Other Documents" are enclosed.

In accordance with the provisions of 37 C.F.R. §1.97, this statement is being filed (CHECK ONE):

- ☒ (1) within three (3) months of the Filing Date, before the mailing date of a First Office Action on the merits, or before the mailing date of a First Office Action on the merits after the filing of a request for continued examination under 37 C.F.R. §1.114; or
- ☐ (2) after the period defined in (1) but before the mailing date of a Final Rejection or Notice of Allowance, and
- ☐ the requisite Statement is below, OR
- ☐ the requisite fee of \$180.00 under Rule 1.17(p) is included herein, or

- ☐ (3) after the mailing date of a Final Rejection or Notice of Allowance but on or before the payment of the Issue Fee, AND the requisite Statement is below AND the requisite fee of \$180.00 under Rule 1.17(p) is included herein.

STATEMENT

Applicants hereby state that:

- ☒ Each item of information contained in the Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart application or by the USPTO in a related application not more than three months prior to the filing date of the Information Disclosure Statement

- ☐ If this box is checked, Applicant provides the following:

Certification Under 37 C.F.R. §1.704(d)

In accordance with 37 C.F.R. §1.704(d), the undersigned hereby certifies that each item listed on the enclosed Form 1449 was first cited in a communication from a foreign patent office in a counterpart application, and that this communication was not received by any individual designated in 37 C.F.R. §1.56(c) more than thirty (30) days prior to the filing of this Information Disclosure Statement.

- ☐ The Examiner is hereby advised of the following co-pending U.S. applications. A copy of each U.S. patent application publication (if published) or application (if not published) is enclosed.

Application No.

Filing Date

Group

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

FEE AUTHORIZATION

Should any fee associated with the submission of this paper not be attached hereto as a check, the Commissioner is authorized to charge the missing fee to our Deposit Account, No. 50-3478. Any overpayments should be credited to said Deposit Account.

Respectfully submitted,

HAMRE, SCHUMANN, MUELLER &
LARSON, P.C.

Post Office Box 2902

Minneapolis, MN 55402-0902

(612) 455-3800

Dated: Feb. 12, 2008

By: 

Douglas P. Mueller

Rdg. No. 30,300

DPM:mkc